<DOC>
	<DOCNO>NCT00719199</DOCNO>
	<brief_summary>Open-label phase 1b trial . Study treatment administer 3 week cycle . There two distinct part study : - Part 1 : Dose escalation IMO-2055 - Part 2 : Once recommend phase 2 dose find additional tolerability pharmacodynamics explore</brief_summary>
	<brief_title>Study FOLFIRI Plus Cetuximab Plus IMO-2055 Patients With Colorectal Cancer</brief_title>
	<detailed_description>- Part 1 : Dose escalation IMO-2055 , include 3 dose group . Once recommended phase 2 dosage ( RP2D ) IMO-2055 give concomitantly FOLFIRI cetuximab find select cohort expand additional 6 9 patient ( total 12 patient ) confirmation RP2D combination treatment regimen . - Part 2 : A final cohort 12 patient ( Cohort 6 ) enrol simultaneously explore tolerability pharmacodynamics patient treat RP2D IMO-2055 combination FOLFIRI cetuximab .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients must satisfy follow inclusion criterion order eligible study : 1 . Signed write informed consent prior studyspecific screening procedure , understand patient right withdraw study time , without prejudice . 2 . Male female patient age ≥ 18 year . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 4 . Histologically confirm adenocarcinoma colon rectum advance metastatic disease . 5 . Patients whose disease recur progressed completion least one ( 1 ) standard regimen cytotoxic agent . Patients may number prior regimen long entry criterion meet . Preferred patient progress first line FOLFIRI FOLFOX without bevacizumab . Patients may prior exposure monoclonal antibody cetuximab , bevacizumab panitumumab . 6 . All clinically significant adverse event prior chemotherapy , surgery radiotherapy must resolve CTCAE v3.0 grade ≤ 1 . Neuropathy CTCAE v3.0 grade ≤ 2 allow neuropathy closely monitor throughout trial . 7 . A minimum 4 week must occur last receipt chemotherapy , biotherapy , radiotherapy , major surgery registration . 8 . Be willing able comply protocol duration study . 9 . If prior malignancy diagnose , colorectal , evidence disease cancer , therapy cancer recover grade 1 less toxicity prior treatment . Patients follow excluded participation study : Disease 1 . Known central nervous system ( CNS ) metastases unless control ≥ 4 month without use steroid . 2 . Patients candidate neoadjuvant `` conversion '' therapy follow curative surgery . Prior Treatments 3 . Prior pelvic irradiation . 4 . Administration investigational agent ( therapeutic diagnostic ) , within 4 week prior first study dose . 5 . Patients prior history cetuximab hypersensitivity may admit Part 1 study . Other Concomitant Medications 6 . Chronic oral intravenous corticosteroid . ( Note : Doses ≤ 5 mg/day prednisone equivalent permit . Topical , inhale intraarticular corticosteroid allow . ) 7 . Therapeutic anticoagulation ( warfarin &gt; 1 mg/day heparin ) . Lowdose warfarin port prophylaxis lowmolecular weight heparin therapeutic dos allow . Laboratory 8 . The following laboratory result : Hemoglobin &lt; 9.0 g/dL Absolute neutrophil count &lt; 1.5 x 109/L Platelet count &lt; 100 x 109/L Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) ALT AST &gt; 2.5 x ULN ( &gt; 5 x ULN liver metastasis present ) Alkaline phosphatase &gt; 2.5 x ULN ( &gt; 5 x ULN liver metastasis present , &gt; 10 x ULN case presence bone metastasis ) Serum creatinine &gt; 1.5 x ULN Albumin &lt; 2.5 g/dL Other Conditions Procedures 9 . Grade 3 4 nonhematological toxicity febrile neutropenia relate previous irinotecanbased regimen . 10 . Homozygous UGT1A1*28 allele . 11 . Known hypersensitivity murine proteins oligonucleotides . 12 . Pregnant breastfeed woman . 13 . Women childbearing potential either positive pregnancy test baseline . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 14 . Men woman childbearing potential refuse unable use acceptable mean contraception study . 15 . History uncontrolled seizure , central nervous system disorder psychiatric disability judge Investigator clinically significant precluding inform consent interfere compliance . 16 . Pre exist autoimmune antibodymediated disease , include , limited , follow : organ allograft , systemic lupus erythematosus , rheumatoid arthritis , multiple sclerosis , Sjogren 's syndrome autoimmune thrombocytopenia , know Gilbert 's syndrome . 17 . Signs/symptoms bowel obstruction pseudoobstruction history inflammatory bowel disease . 18 . Clinically significant ( i.e. , active ) cardiac disease ( e.g. , congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 6 month . 19 . Interstitial pneumonia extensive symptomatic fibrosis lung . 20 . Serious uncontrolled concomitant disease , intercurrent infection , know medical condition opinion Investigator put patient increase risk significant toxicity treatment , hypertension , uncontrolled medication , chronic hepatitis ( viral ) cirrhosis , know human immunodeficiency virus ( HIV ) infection , uncontrolled diabetes . 21 . Legal incapacity limit legal capacity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>metastatic cancer</keyword>
	<keyword>prior therapy</keyword>
	<keyword>1b</keyword>
</DOC>